Shares closed at $731.77 on Tuesday, marking a third consecutive day of losses and finishing 10.88% below the 52-week high of $821.11 set in January.
Regeneron underperformed competitors, with Amgen down 0.18%, Moderna down 3.20%, and Gilead Sciences up 1.18%. Trading volume was 557,715, below the 50-day average.
The decline occurred during a rough session for the S&P 500 and Dow Jones, reflecting wider market pressures affecting pharmaceutical stocks and broader investor sentiment.
Regeneron's stock is falling despite multiple FDA approvals. Is Wall Street overlooking a major comeback story?
How is Regeneron managing its two biggest drugs, with one's sales soaring while the other's are plunging?
Following Gilead's $7.8B deal, how will the cancer therapy market shift for competitors like Regeneron?
As rivals acquire new tech, is Regeneron's massive R&D spending a smarter bet for long-term growth?
Regeneron is offering a new gene therapy for free. What is the business strategy behind this unprecedented move?